1. Market Research
  2. > Pharmaceutical Market Trends
  3. > US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook

US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook

  • March 2016
  • -
  • International Market Analysis Research and Consult
  • -
  • 51 pages

The report entitled “US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook” provides a comprehensive insight into the historical and current trends as well as the future prospects of the US generics market. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generics market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generics market in any form.

What We Have Achieved in This report?

Historical, current and future sales trends in the US generics market
Historical, current and future prescription trends in the US generics market
Performance of the US generics market compared to the pharmaceutical market
Performance of the US generics market compared to other major markets
Market structure of the US generics market
Competitive landscape in the US generics market
Top US generic drug manufacturers and their market shares
Distribution of generics in the US
Top US generic distributors and their market shares
Most prescribed generic drugs in the US
Pricing analysis of generic drugs
Value chain analysis of generic drugs in the US
Regulations in the US generics market
Manufacturing process of generics
Machinery and raw material requirements for manufacturing generics
Key success and risk factors in the US generics market

Table Of Contents

US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook
1 Research Methodology and Market Definitions
2 Report Summary
3 US Generics Market - Introduction
3.1 What are Generics?
3.2 Unbranded and Branded Generics
3.3 Authorized Generics
3.4 Commoditised and Specialty Generics
4 Why is the US Generics Market so Lucrative
4.1 Patent Expiry of Blockbuster Drugs
4.2 Significant Price Differential Between Generics and Innovator Drugs
4.3 Savings for the Government and Third Party Payers
4.4 Incentives for Dispensing and Prescribing Generics
4.5 Reimbursement and Lower Copayments
4.6 Biosimilars
5 Global Generics Market
5.1 Current and Historical Market Trends
5.2 Market Breakup by Country: The United States Represents the World's Biggest Market
5.3 Market Forecast
6 US Generics Market
6.1 US Pharmaceutical Market - Current and Historical Market Trends
6.2 US Pharmaceutical Market - Share of Branded and Generic Drugs
6.3 US Generics Market - Current and Historical Sales Trends
6.4 US Generics Market - Current and Historical Volume Trends
6.5 US Generics Market - Market Breakup By Segment
7 US Generics Market- Competitive Landscape
7.1 US Generics Market - Competitive Structure
7.2 US Generics Market - Sales Breakup of Key Players
7.3 US Generics Market - Volume Breakup of Key Players
7.4 US Generics Market - Most Prescribed Generic Drugs
7.5 US Generics Market - Market Breakup By Distribution
7.6 US Generics Market - Pricing Dynamics
8 US Generics Market - Value Chain Analysis
8.1 Research and Development
8.2 Manufacturing
8.3 Marketing and Distribution
9 Regulations in the US Generics Industry
9.1 Overview of Pharmaceutical Regulations
9.2 Drug Applications
9.3 Patents and Market Exclusivity
9.4 Regulatory Requirement For Generics
9.5 The Hatch-Waxman Act
9.6 Possible Certifications
9.7 Other Important Considerations
10 US Generics Market: Key Success Factors
11 US Generics Market: Road Blocks
12 Requirements for Setting Up a Generic Drug Manufacturing Plant
12.1 Manufacturing Process
12.2 Raw Material Requirements
12.3 Machinery and Infrastructure Requirements
13 US Generic Market - Key Company Profiles
13.1 Teva
13.2 Mylan
13.3 Actavis
13.4 Sandoz
13.5 Sun Pharma
13.6 Par Pharmaceuticals
13.7 Endo Pharmaceuticals
13.8 Lupin Pharmaceuticals
13.9 Dr Reddy's
13.10 Hospira

List of Figures

Figure 3 1: Structure of the Pharmaceutical Industry
Figure 3 2: Classification of Generics
Figure 4 1: United States: Patent Expiry Exposure (in Billion US$)
Figure 4 2: United States: Savings From Generic Drugs (in Billion US$), 2005-2015
Figure 5 1: Global: Generics Market: Sales Value (in Billion US$), 2011-2015
Figure 5 2: Global: Generics Market: Sales Volume (in Billion SU), 2011-2015
Figure 5 3: Global: Generics Market: Sales Value Breakup By Country (in %), 2015
Figure 5 4: Global: Generics Market: Sales Volume Breakup by Country (in %), 2015
Figure 5 5: Global: Generics Market Forecast: Sales Value (in Billion US$), 2016-2021
Figure 5 6: Global: Generics Market: Sales Volume (in Billion SU), 2016-2021
Figure 6 1: US: Pharmaceutical Market: Sales Volume (in Million Prescriptions), 2011-2015
Figure 6 2: US: Pharmaceutical Market: Sales Value (in US$ Billion), 2011-2015
Figure 6 3: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2011 and 2015
Figure 6 4: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2011 and 2015
Figure 6 5: US: Generics Market: Sales Value (in Billion US$), 2011-2015
Figure 6 6: US: Generics Market Forecast: Sales Value (in US$ Billion), 2016-2021
Figure 6 7: US: Generics Market: Sales Volume (in Million Prescriptions), 2011-2015
Figure 6 8: US: Generics Market Forecast: Sales Volume (in Million Prescriptions), 2016-2021
Figure 6 9: US: Generics Market: Market Breakup by Segment (in %), 2011-2015
Figure 7 1: United States: Generics Market: Sales Share of Top Players (in %), 2015
Figure 7 2: United States: Generics Market: Volume Share of Top Players (in %), 2015
Figure 7 3: United States: Generics Market: Volume Share by Distribution (in %), 2015
Figure 7 4: United States: Generic Drug Prices as a Percentage of Branded Drug Prices - Based on Number of Competitors (in Billion US$)
Figure 8 1: United States - Generics Market - Value Chain Analysis

List of Tables

Table 4 1: United States: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$)
Table 5 1: Global - Generics Market: Sales, Volume and Growth of Major Markets, 2015
Table 7 1: United States: Generics Market: Sales Performance of Top Players (in US$ Million), 2015
Table 7 2: United States: Generics Market: Volume Performance of Top Players (in Million Prescriptions), 2015
Table 7 3: United States: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015
Table 9 1: United States: Overview of Pharmaceutical Regulations

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.